Oxybutynin Shows Promise in Reducing Hot Flashes for Men Undergoing Prostate Cancer Treatment

A medication commonly used to treat overactive bladder, oxybutynin, has demonstrated significant effectiveness in reducing hot flashes experienced by men receiving androgen-deprivation therapy (ADT) for prostate cancer. A phase 2 clinical trial published in the Journal of Clinical Oncology revealed that oxybutynin outperformed a placebo in alleviating both the frequency and intensity of these bothersome symptoms.

The Burden of Hot Flashes in Prostate Cancer Patients

Hot flashes affect an estimated 60% to 80% of men undergoing ADT, a common treatment for prostate cancer [1]. These symptoms can disrupt sleep, negatively impact mood, and diminish overall quality of life. For some patients, the severity of hot flashes is substantial enough to consider discontinuing treatment.

Study Findings: Oxybutynin vs. Placebo

The Alliance A222001 trial, involving 88 men with prostate cancer experiencing frequent hot flashes while on ADT, randomly assigned participants to receive either 2.5 mg or 5 mg of oxybutynin twice daily, or a placebo, for six weeks [2]. The primary outcome measured was the change in patient-reported hot flash scores.

Key findings from the study include:

• Patients receiving the higher dose of oxybutynin (5 mg) experienced the greatest benefit, with an average reduction of nearly seven hot flashes per day, compared to approximately two fewer hot flashes per day in the placebo group [3].
• More than three-quarters of men in the 5 mg oxybutynin group achieved at least a 50% reduction in hot flash severity.
• Patients taking oxybutynin similarly reported improvements in sleep, work, social activities, and overall quality of life.

Safety and Tolerability

The study demonstrated a favorable safety profile, with no treatment-related serious adverse events reported [4]. The most common side effect observed was dry mouth, which was more prevalent at higher doses.

Expanding Treatment Options

“Oxybutynin demonstrated clear and clinically meaningful improvements in both hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer,” said Bradley J. Stish, MD, Radiation Oncologist at Mayo Clinic Comprehensive Cancer Center [3]. “These results provide strong support for its use as an effective management option for this challenging and often overlooked side effect of prostate cancer treatment.”

Future Directions

While these findings are promising, researchers emphasize the need for larger studies to confirm the results and determine the optimal dosage of oxybutynin for managing ADT-associated hot flashes. This research expands the available options for clinicians and patients seeking to manage this challenging side effect of prostate cancer treatment.